BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Køstner AH, Sorensen M, Olesen RK, Grønbæk H, Lassen U, Ladekarl M. Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability. ScientificWorldJournal 2013;2013:931972. [PMID: 23431262 DOI: 10.1155/2013/931972] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Sacco R, Mismas V, Romano A, Bertini M, Bertoni M, Federici G, Metrangolo S, Parisi G, Tumino E, Bresci G, Giacomelli L, Marceglia S, Bargellini I. Assessment of clinical and radiological response to sorafenib in hepatocellular carcinoma patients. World J Hepatol 2015; 7(1): 33-39 [PMID: 25624994 DOI: 10.4254/wjh.v7.i1.33] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kambhampati S, Bauer KE, Bracci PM, Keenan BP, Behr SC, Gordan JD, Kelley RK. Nivolumab in patients with advanced hepatocellular carcinoma and Child‐Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. Cancer 2019;125:3234-41. [DOI: 10.1002/cncr.32206] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 10.7] [Reference Citation Analysis]
3 McNamara MG, Knox JJ. Systemic therapy for hepatocellular carcinoma. Hepat Oncol 2014;1:23-38. [PMID: 30190939 DOI: 10.2217/hep.13.10] [Reference Citation Analysis]
4 Addissie BD, Roberts LR. Classification and staging of hepatocellular carcinoma: an aid to clinical decision-making. Clin Liver Dis. 2015;19:277-294. [PMID: 25921663 DOI: 10.1016/j.cld.2015.01.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
5 Mori S, Kita J, Kato M, Shimoda M, Kubota K. Usefulness of a new inflammation-based scoring system for prognostication of patients with hepatocellular carcinoma after hepatectomy. Am J Surg 2015;209:187-93. [PMID: 24950991 DOI: 10.1016/j.amjsurg.2014.02.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
6 McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A, Tariq N, Valle JW, Hubner RA, Knox JJ, Amir E. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis. Eur J Cancer 2018;105:1-9. [PMID: 30384012 DOI: 10.1016/j.ejca.2018.09.031] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
7 Won JK, Yu SJ, Hwang CY, Cho SH, Park SM, Kim K, Choi WM, Cho H, Cho EJ, Lee JH, Lee KB, Kim YJ, Suh KS, Jang JJ, Kim CY, Yoon JH, Cho KH. Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. Hepatology 2017;66:855-68. [PMID: 28439950 DOI: 10.1002/hep.29237] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
8 Sánchez AIP, Roces LV, García IZ, López EL, Hernandez MAC, Parejo MIB, Peña-Díaz J. Value of α-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. Oncol Lett 2018;15:8863-70. [PMID: 29805623 DOI: 10.3892/ol.2018.8400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
9 Kim KJ, Kim JH, Lee SJ, Lee EJ, Shin EC, Seong J. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. Oncotarget. 2017;8:41242-41255. [PMID: 28465485 DOI: 10.18632/oncotarget.17168] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 11.3] [Reference Citation Analysis]
10 Ho C, Lin K, Shen R, Gu D, Lee S, Su W, Jou Y. Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.04.008] [Reference Citation Analysis]
11 Turco S, El Kaffas A, Zhou J, Lutz AM, Wijkstra H, Willmann JK, Mischi M. Pharmacokinetic Modeling of Targeted Ultrasound Contrast Agents for Quantitative Assessment of Anti-Angiogenic Therapy: a Longitudinal Case-Control Study in Colon Cancer. Mol Imaging Biol 2019;21:633-43. [PMID: 30225758 DOI: 10.1007/s11307-018-1274-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Bansal S, Berk M, Alkhouri N, Partrick DA, Fung JJ, Feldstein A. Stearoyl-CoA desaturase plays an important role in proliferation and chemoresistance in human hepatocellular carcinoma. J Surg Res 2014;186:29-38. [PMID: 24135379 DOI: 10.1016/j.jss.2013.07.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
13 Bouattour M, Payancé A, Wassermann J. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol 2015; 7(20): 2245-2263 [PMID: 26380650 DOI: 10.4254/wjh.v7.i20.2245] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
14 Wang TH, Wu CH, Yeh CT, Su SC, Hsia SM, Liang KH, Chen CC, Hsueh C, Chen CY. Melatonin suppresses hepatocellular carcinoma progression via lncRNA-CPS1-IT-mediated HIF-1α inactivation. Oncotarget 2017;8:82280-93. [PMID: 29137263 DOI: 10.18632/oncotarget.19316] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
15 Hwang CY, Yu SJ, Won JK, Park SM, Noh H, Lee S, Cho EJ, Lee JH, Lee KB, Kim YJ, Suh KS, Yoon JH, Cho KH. Systems analysis identifies endothelin 1 axis blockade for enhancing the anti-tumor effect of multikinase inhibitor. Cancer Gene Ther 2021. [PMID: 34363028 DOI: 10.1038/s41417-021-00373-x] [Reference Citation Analysis]
16 Wörns MA, Galle PR. Sorafenib for the treatment of hepatocellular carcinoma. Hepat Oncol 2014;1:189-204. [PMID: 30190954 DOI: 10.2217/hep.13.20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
17 Hsu CH, Shen YC, Shao YY, Hsu C, Cheng AL. Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. J Hepatocell Carcinoma 2014;1:85-99. [PMID: 27508178 DOI: 10.2147/JHC.S45040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
18 Callegari E, Elamin BK, Sabbioni S, Gramantieri L, Negrini M. Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Onco Targets Ther. 2013;6:1167-1178. [PMID: 24039437 DOI: 10.2147/ott.s36161] [Cited by in Crossref: 19] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]